Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028)
NCT04295772
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
42
Enrollment
INDUSTRY
Sponsor class
Conditions
HIV-1 Infection
Interventions
DRUG:
DOR/ISL
Sponsor
Merck Sharp & Dohme LLC